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Abstract
Vascular endothelial growth factor receptor 1 (VEGFR1) is a marker for endothelial-specific gene
expression. We previously reported that the human VEGFR1 promoter (between −748 and +284)
contains information for expression in the intact endothelium of transgenic mice. The objective of this
study was to dissect the cis-regulatory elements underlying VEGFR1 promoter activity in vitro and in
vivo. In primary endothelial cells, binding sites for E74-like factor 1 (ELF-1; between −49 and −52),
cyclic adenosine monophosphate response element binding (CREB; between −74 and −81), and early
growth response factor 1/3 (EGR-1/3; between −16 to −25) were shown to play a positive role in gene
transcription, whereas a putative E26 transformation-specificsequence (ETS) motif between −36 and
−39 had a net negative effect on promoter activity. When targeted to the Hprt locus of mice, mutations
of the ELF-1 binding site and the CRE element reduced promoter activity in the embryonic vasculature
and resulted in a virtual loss of expression in adult endothelium. Postnatally, the EGR binding site
mutant displayed significantly reduced promoter activity in a subset of vascular beds. In contrast,
mutation of the −39 ETS site resulted in increased LacZ staining in multiple vascular beds. Together,
these results provide new insights into the transcriptional regulatory mechanisms of VEGFR1.
Introduction
Vascular endothelial growth factor A (VEGF-A) binds to 2 receptors, VEGFR1 (also known as Flt-1) and
VEGFR2 (also known as Flk-1 or KDR). Expression of both receptors is largely restricted to endothelial
cells. The human VEGFR1 promoter has been previously cloned and characterized. A 1-kb region
between −748 and +248 was shown to direct cell type–specific expression in cultured endothelial cells.
Transient transfection assays revealed several positive-acting elements, including consensus sites for
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E26 transformation-specific sequence (ETS; between −49 and −52), cyclic adenosine monophosphate
response element binding (CREB)/activating transcription factor (between −74 and −81), and early
growth response factor (EGR; between −16 and −25).  In contrast, a putative ETS consensus element
between −36 and −39 was shown to repress promoter activity.
Subsequently, we reported that a 1-kb fragment of the human VEGFR1 promoter (between −748 and
+284) contains information for endothelial-restricted expression in transgenic mice.  In the latter
study, a single copy of the VEGFR1 promoter was targeted to the Hprt locus, thus providing a means to
control for the effects of copy number and integration site on expression. In the current study, we used
an identical Hprt targeting strategy to evaluate the activity of the VEGFR1 promoter containing a point
mutation of 1 of the 2 ETS motifs, the CRE site, or the EGR binding element. Our data suggest that each
of these DNA elements contributes in a unique way to the expression of VEGFR1 in vivo.
Methods
Plasmid constructions
Construction of VEGFR1 wild-type and mutant promoter constructs used in transient transfection
assays and Hprt-locus targeting is detailed in supplemental Methods (available on the Blood website;
see the Supplemental Materials link at the top of the online article).
Cell culture
Human umbilical vein endothelial cells (HUVECs), human coronary artery endothelial cells (HCAECs),
and human pulmonary artery endothelial cells (HPAECs) were purchased from Lonza and cultured in
endothelial cell medium supplemented with EGM-2-MV bullet kit (Lonza). Murine endothelial cells
were harvested from the hearts of Hprt-targeted mice as detailed in supplemental Methods.
Transient transfection assays
Transient transfection and cotransfections were carried out as described previously  and in
supplemental Methods.
ChIP
Chromatin immunoprecipitation (ChIP) assay was performed using a chromatin immunoprecipitation
assay kit (Upstate) according to the manufacturer's instructions and as detailed in supplemental
Methods.
Electrophoretic gel mobility shift assays
Nuclear extraction and electrophoretic gel mobility shift assays (EMSAs) were carried out as described
previously  and in supplemental Methods.
Transfection with siRNA
HUVECs were transfected with siRNAs against E74-like factor 1 (ELF-1) or ETS-1 (Dharmacon) as
previously described.  siRNA sequences are shown in supplemental Table 1.
Quantitative real-time polymerase chain reaction
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Primer sequences are shown in supplemental Table 1.
Generation and analysis of Hprt-targeted transgenic mice
The generation and analysis of transgenic mice carrying promoter-reporter genes were approved by the
Institutional Animal Care and Use Committee at Beth Israel Deaconess Medical Center. BK4 ES cells
were transfected with the Hprt targeting vectors and injected into blastocysts as previously described
(and supplemental Methods). Resulting chimeric males were bred with C57BL/6 females to obtain
agouti offspring. The agouti female offspring were backcrossed with C57BL/6 males to generate
hemizygous male F2 mice. Genotyping was performed by PCR analysis. Whole-mount and tissue section
LacZ and CD31 staining of embryonic and adult tissues, β-galactosidase activity assays, and tumor
xenografts were carried out as previously described  (and supplemental Methods).
Statistical analyses
Data were expressed as mean plus or minus SE. The statistical significance of differences of the means
was determined by 1-way analysis of variance and multiple comparisons by Tukey-Kramer multiple
range test.
Results
Phylogenic footprinting of VEGFR1 promoter
Previous studies have implicated a role for 2 ETS consensus elements, a CREB/ATF binding site and an
EGR binding motif, in mediating basal or inducible expression of VEGFR1.  Recognizing that
functional regulatory regions are more highly conserved than neutrally evolving sequences, we used a
comparative genomics approach to determine the extent to which these sites are evolutionarily
conserved and to identify other potentially relevant cis-regulatory elements. Using University of
California Santa Cruz (UCSC) Genome Browser  and ECR Browser,  we identified 3 regions of
significant conservation between −1300 and +300: region 1 between −6 and −124, region 2 between
−244 and −486, and region 3 between −659 and −1199 (supplemental Figures 1-2). Region 1 contains
the EGR binding element (between −16 and −25), the ETS motif between −49 and −52 (referred to
hereafter as −52 ETS), the −36 to −39 ETS site (referred to hereafter as −39 ETS), and the CRE element
between −74 and −81 (Figure 1). These 4 sites demonstrate remarkable conservation across all
vertebrae. A conserved transcription factor binding site search using MultiTF  identified potential
transcription factors with binding sites overlapping 3 of the 4 sites. The EGR site could potentially bind
EGR1, EGR2, EGR3, EGR4, E2F1, E2F3, E2F4, TFDP1, or WT1. The −52 ETS could bind to several ETS
family members, including ELF1/2 and ETV4. The −39 ETS site is not directly identified by MultiTF as a
consensus binding site, likely due to the mismatch between the nucleotides flanking its core GGAA
sequence (GGGAAA) and the consensus AGGAAG required by most ETS-type matrices in TRANSFAC.
Finally, the CRE-type site could potentially bind CREB1, CREM, ATF1, ATF2, ATF3, ATF4, ATF5, ATF6,
ATF7, JUN, NR2F2, and NKX2-1.
Consensus motifs for ETS, CREB/ATF, and EGR are involved in mediating VEGFR1 promoter activity in
cultured human primary endothelial cells
To confirm a functional role for the −25 EGR binding element, the −52 and −39 ETS motifs, and the −81
CRE site in mediating VEGFR1 expression in vitro, we generated VEGFR1 promoter luciferase
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transiently transfected into primary human endothelial cells, including HUVECs, HCAECs, and
HPAECs. Mutation of the −52 ETS motif resulted in complete loss of expression, whereas mutation of
the CRE and EGR elements resulted in a significant, though less dramatic, reduction in promoter
activity (Figure 2B). In contrast, a mutation of the −39 ETS site yielded increased promoter activity (
Figure 2B). Although the latter result was consistently observed in multiple experiments and endothelial
cell types, it reached statistical significance in HCAEC alone. Thus, consensus elements for ETS (−49 to
−52), CREB/ATF (−74 to −81), and EGR (−16 to −25) play a positive role in VEGFR1 expression,
whereas a putative ETS motif between −36 and −39 has a net negative effect on promoter activity.
ELF-1 and SP1 interact with the −52 ETS motif to transactivate the VEGFR1 promoter in cultured human
primary endothelial cells
The transient transfection data suggested that the −52 ETS site plays a particularly important role in
mediating VEGFR1 expression in endothelial cells. To identify the factor that binds to this site, we
carried out EMSAs. Incubation of a radiolabeled probe spanning the −52 ETS site with nuclear extract
from HUVECs resulted in several DNA-protein complexes (Figure 3A lane 2). Four of the complexes (
Figure 3A labeled a-d) were inhibited by addition of cold wild-type ETS competitor, but not a mutant
ETS competitor (Figure 3A lanes 3-6). Supershift assays were carried out with antibodies to ETS factors
that have been previously implicated in endothelial cell gene regulation, including ETS-1, ETS-2, ELF-1,
FLI-1, ERG, NERF, and PEA3 (Figure 3B shows ETS-1, ETS-2, and ELF-1). Of these antibodies, ELF-1
resulted in significant inhibition of a specific DNA-protein complex (Figure 3B lane 3). This complex
migrated at the same distance as recombinant in vitro translated ELF-1 protein bound to DNA (Figure 3
B compare lanes 12 and 2). Recombinant ELF-1–DNA complex was inhibited by anti–ELF-1 antibody (
Figure 3B lane 13), indicating that the ELF-1 antibody does indeed inhibit rather than supershift the
DNA-protein complex. Antibody to ETS-1 had a slight inhibitory effect on the specific DNA-protein
complex (Figure 3B lane 5). However, given that ETS-1 is considerably smaller than ELF-1 (51 and 98
kDa, respectively), it is unlikely that the antibody is recognizing ETS-1 alone or bound together with
ELF-1 to DNA (the DNA-protein complexes would migrate faster or slower than the ELF-1–DNA
complex). As a positive control for ETS-1 binding and supershifting activity of the ETS-1 antibody, a
radiolabeled probe spanning a consensus ETS-1 binding motif was incubated with recombinant ETS-1.
As shown in Figure 3C, ETS-1 protein bound to the consensus ETS-1 binding, but not the −52 ETS
probe. The resulting DNA-protein complex was supershifted by ETS-1 antibody. Thus, the −52 site binds
ELF-1, but not ETS-1.
To provide further evidence for the selective involvement of ELF-1 in mediating VEGFR1 expression,
HUVECs were transfected with siRNA against ELF-1 and/or ETS-1. ELF-1–siRNA resulted in 70%
reduction in ELF-1 mRNA levels, and 30% reduction in VEGFR1 mRNA levels (Figure 3D). By contrast,
siRNA-mediated knockdown of ETS-1 (80% reduction) had no effect on VEGFR1 expression. As a
positive control, ETS-1 knockdown resulted in 70% reduction of its known target gene, monocyte
chemoattractant protein 1 (not shown). ETS-1 knockdown did not lead to further reduction of VEGFR1
mRNA levels in ELF-1–deficient HUVECs, arguing against a functional interaction between these 2
factors (Figure 3D).
Unexpectedly, preincubation with anti-SP1 antibody resulted in a partial supershift of the slowest
migrating DNA-protein complex (Figure 3B lane 4; the partial nature of the supershift may be explained
by limiting amounts of antibody or the existence of a second DNA-protein complex that lacks SP1).
Incubation of radiolabeled probe with in vitro translated SP1 resulted in a DNA-protein complex of
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similar size to that obtained with nuclear extracts (Figure 3B compare lanes 9 and 2). The latter complex
was supershifted with anti-SP1 antibody (Figure 3B lane 10).
To investigate whether ELF-1 and SP1 bind to the VEGFR1 proximal region in endothelial cells, ChIP
assay was performed. Formalin-fixed genomic DNA-protein complexes from HUVECs were sheared by
sonication. Resulting small DNA-protein complexes were immunoprecipitated with antibodies to ELF-1
and SP1 (or control immunoglobulin G [IgG]), and the resulting products were used as template in a
PCR reaction containing primers specific for the immediate upstream promoter of VEGFR1. Real-time
PCR was used to calculate binding intensities. As shown in Figure 3E, ELF-1 and SP1, but not control
IgG, bound to the proximal promoter region.
To determine whether ELF-1 and/or SP1 transactivate the VEGFR1 promoter, cotransfection assays
were carried out in HEK293 cells. An advantage of using HEK293 cells is that they express low,
nonsaturating levels of endothelial-associated ETS factors, including ELF-1. Overexpression of ELF-1
resulted in significant (3.4-fold) induction of VEGFR1 promoter activity (Figure 3F). Mutation of the
−52 ETS site abrogated ELF-1–mediated transactivation of the promoter. Expression of SP1 also
induced VEGFR1 activity (3.6-fold; Figure 3F). Interestingly, this effect was also abrogated by mutation
of the −52 ETS site. Cotransfection of ELF-1 and SP1 resulted in an additive effect on promoter activity
(6.0-fold). The cotransfection experiments were repeated in HUVECs. Although absolute levels of
induction were lower compared with HEK293 cells, ELF-1 and SP1 each transactivated the wild-type,
but not the −52 ETS mutant VEGFR1 promoter, and combined transfection with ELF-1 and SP1 had an
additive effect (Figure 3G). Together with the EMSA results, these data suggest that ELF-1 and SP1 both
bind to the −52 ETS motif and transactivate VEGFR1.
The −39 ETS motif is bound by SP1, but not ETS factor(s), in cultured human primary endothelial cells
Our transfection data suggested that the −39 ETS motif plays a negative role in VEGFR1 transcription.
To determine whether this site binds nuclear protein, we performed EMSA using a radiolabeled probe
spanning the −39 ETS site and nuclear extract from HUVECs. Several DNA-protein complexes were
observed (Figure 4A lane 2). However, only 1 of these (the slowest migrating) was inhibited by cold wild-
type ETS competitor, but not mutated ETS competitor (Figure 4A lanes 3-4). Supershift assays were
carried out as described with the −52 ETS probe. Antibodies against the various ETS factors failed to
supershift or inhibit the specific DNA-protein complex (Figure 4A lanes 5 and 7 show ELF-1 and ETS-1).
In contrast, anti-SP1 antibody resulted in a supershifted complex (Figure 4A lane 6). In vitro translated
SP1 protein resulted in a specific DNA-protein complex compatible with that observed with nuclear
extracts (Figure 4A compare lanes 10 and 2). These findings, together with the observation that a
mutation of the −39 ETS motif induces promoter activity, whereas a mutation of the −52 ETS motif
(leaving the −39 ETS motif intact) abrogates SP1- and ETS-mediated transactivation of the VEGFR1
promoter, suggest that the −39 ETS site inhibits expression by binding and sequestering SP1. Consistent
with this conclusion, binding of recombinant SP1 to the −52 ETS motif was inhibited to a similar degree
by same-fold cold competitor containing either the −52 ETS or −39 ETS motif (supplemental Figure 3).
The CRE element is bound by CREB and the EGR binding element is bound by EGR-1 in cultured
human primary endothelial cells
The transfection data pointed to a positive role for the CREB/ATF and EGR binding sites in mediating
basal activity of the VEGFR1 promoter. To determine whether these sites bind to nuclear protein, we
performed EMSA using radiolabeled probes spanning each motif. Incubation of the CRE probe with
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nuclear extract from endothelial cells resulted in a specific DNA-protein complex that was competed by
self- but not mutant cold probe (Figure 4B lanes 3-4). The complex was supershifted by addition of anti-
CREB antibody (Figure 4B lane 5), but not by antibody against ATF2 or IgG (Figure 4B lanes 6-7).
Incubation of the probe containing the EGR binding site resulted in a DNA-protein complex that was
partially inhibited by anti–EGR-1 antibody but not anti–EGR-3 antibody or control IgG (Figure 4C).
The appearance of this band required a long exposure time (48 hours). To verify that the EGR binding
site was capable of binding to EGR protein, the labeled probe was incubated with recombinant EGR-1 or
EGR-3. Each factor formed specific complexes that were inhibited by cold wild-type but not mutant
competitor and were supershifted by their respective antibody (Figure 4D-E). Thus, the EGR binding
site has the capacity to bind both EGR-1 and EGR-3.
Consensus motifs for ETS, CREB/ATF, and EGR mediate VEGFR1 promoter activity in vivo
To determine the role of the various cis-regulatory motifs in directing expression of VEGFR1 in vivo, the
wild-type or mutant VEGFR1 promoters were coupled to LacZ and the resulting constructs targeted to
the Hprt locus of mice using homologous recombination. Hprt-targeted lines were bred to generate
stable lines. Reporter gene activity was assayed in 6- to 8-week-old F2 males. To compare whole-mount
LacZ staining of wild-type and mutant VEGFR1 mouse tissues, organs were harvested from age- and
generation-matched male mice, and stained simultaneously with the same X-Gal–containing solution.
LacZ staining of the diaphragm (a thin blood vessel–rich skeletal muscle that is particularly amenable to
whole-mount staining) revealed vascular expression in wild-type VEGFR1 mice, but not in mice carrying
a mutation of the −52 ETS or CRE sites (Figure 5). Compared with the wild-type promoter, the EGR
mutant demonstrated lower expression in the diaphragm, whereas the −39 ETS mutant revealed higher
activity (Figure 5). Whole-mount stains of the heart revealed LacZ expression in all lines, with highest
expression in the −39 ETS mutant line followed by wild-type, EGR mutant, −52 ETS mutant, and CRE
mutant lines (supplemental Figure 3). The pattern was similar in the lung, with the notable exception
that reporter gene activity was comparable in EGR mutant and wild-type lines (supplemental Figure 4).
In tissue sections of Hprt-targeted adult mice carrying wild-type, −39 ETS mutant, or EGR mutant
VEGFR1 promoters, LacZ staining colocalized with CD31 in the endothelial lining of vessels in all organs
examined except the liver (Figure 6 shows heart, lung, kidney, and skeletal muscle). In addition,
reporter gene expression was detectable in cardiomyocytes and occasional arterial smooth muscle cells.
In the −52 ETS and CRE mutant mice, LacZ expression was detected in cardiomyocytes and vascular
smooth muscle cells, but was undetectable in the endothelium of all organs examined (supplemental
Figure 5 shows kidney, spleen, and lung). None of the Hprt-targeted transgenes was expressed in bone
marrow or peripheral blood cells (not shown).
To quantitate differences in transgene expression, tissues were assayed for β-galactosidase activity. As
shown in Figure 7A, β-galactosidase activity in the −52 ETS mutant line was significantly reduced in the
heart, lung, kidney, and skeletal muscle. In the CRE mutant line, reporter gene activity was lower in the
brain, heart, lung, kidney, and skeletal muscle. The EGR mutant demonstrated reduced β-galactosidase
activity in the kidney and skeletal muscle, but not lung. In contrast to a clear increase in X-Gal reaction
product in whole-mount organs of −39 ETS mutant mice, there were no significant differences in
activity between wild-type and −39 ETS mutant mice. Given that the whole-mount staining of mutant
and wild-type organs was always carried out in parallel in multiple independent animals and the results
were documented side by side, we conclude that LacZ staining is a more sensitive assay than β-
galactosidase activity measurements.
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To determine whether the profound changes associated with mutation of −52 ETS motif and the CRE
site manifested during development, we examined LacZ expression in utero. Embryonic day (E)–9.5 to
E10.5 embryos carrying the wild-type VEGFR1 promoter demonstrated LacZ expression throughout the
vasculature (supplemental Figure 6). A similar pattern was observed in mice carrying a mutation of the
−39 ETS and EGR sites (data not shown). Mutation of the −52 ETS motif and the CRE site resulted in
significantly reduced expression of LacZ (supplemental Figure 6). The majority of β-galactosidase
activity was detected in the endothelium of yolk sac blood vessels and the endothelium of caudal
intersomitic vessels.
We previously demonstrated that the Flt-1 promoter drives expression in the endothelium of tumor
xenografts.  To determine activity of the mutant promoters in tumor vasculature, B16-F1 melanoma and
Lewis lung carcinoma cells were implanted subcutaneously into the flank of Hprt-targeted mice. When
tumors reached approximately 2.5 cm  in volume, the xenografts were harvested, sectioned, and stained
for LacZ. The wild-type and all 4 mutant promoters displayed detectable activity within tumor
endothelium (supplemental Figure 7). The presence of X-Gal reaction product in tumor vessels of the
−52 ETS and CRE mutant lines is in striking contrast to the absence of detectable promoter activity in
surrounding flank tissue including skin, subcutaneous fat, and abdominal wall muscle (not shown).
These findings suggest that the −52 ETS and CRE mutant promoters become reactivated in the context
of the tumor microenvironment and indicate that other cis-regulatory elements are sufficient for
directing expression in this pathologic vascular bed.
ELF-1 and CREB bind to the VEGFR1 transgenic promoter
To investigate whether ELF-1 and CREB bind to the −52 ETS and CRE motifs in vivo, ChIP assay was
performed using endothelial cells cultured from the hearts of −52 ETS and CRE mutant mice. Formalin-
fixed genomic DNA-protein complexes from the murine endothelial cells were sheared by sonication (
Figure 7B). DNA-protein complexes were immunoprecipitated with antibodies to ELF-1, CREB, or
control IgG, and the resulting products were used as template in a PCR reaction containing primers
specific for the VEGR1 transgene. One primer set comprised a forward primer that lies in the human
VEGFR1 promoter and a reverse primer that is complementary to a sequence in the 5′ end of LacZ
cDNA. Because the VEGFR1 gene contains a relatively long 5′ untranslated region (284 bp), we
considered the possibility that the latter primers would not adequately cover the −52 ETS and CRE sites
in sheared DNA. Thus, we confirmed the results using a second set of primers, both of which lie in the
immediate upstream promoter region of human VEGFR1 and have low homology with the mouse
VEGFR1 promoter (supplemental Table 1). In these assays, ELF-1 preferentially bound to the CREm
transgenic promoter, whereas CREB demonstrated preferential binding to the −52 ETS transgenic
promoter (Figure 7C shows the first primer set; similar results were obtained with the second primer
set). These findings demonstrate that ELF-1 and CREB bind to the −52 ETS and CRE sites of the
VEGFR1 promoter, respectively.
Discussion
Morishita et al first reported that a −748 to +248 region of the human VEGFR1 promoter directs
lineage-specific expression in cultured endothelial cells.  Deletion of 4 base pairs from a consensus
CREB/ATF binding motif (ACGT out of TGACGTCA) resulted in an 85% reduction in promoter activity
in bovine aortic endothelial cells.  In a subsequent study, a mutation of the same CRE element
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and +8 resulted in 90% reduction in reporter gene expression in HUVECs.  A mutation of the ETS motif
between −49 and −52 (GGAA to CCAA) was also shown to impair reporter gene expression,  whereas
mutation of the ETS consensus site between −36 and −39 (GGAA to CCAA) resulted in increased
promoter activity (≈1.85-fold).  Our in vitro data confirm a positive role for the −52 ETS and CRE sites
and a negative role for the −39 ETS motif in mediating VEGFR1 promoter activity in primary human
endothelial cells.
Using EMSA and ChIP assays, we have shown that the −52 ETS motif is bound by the ETS factor, ELF-1,
as well as SP1. A functional role for these DNA-protein interactions was evidenced by the ability of ELF-
1 and SP1 to transactivate the wild-type VEGFR1 promoter, but not a promoter containing a mutation of
the −52 ETS site. In EMSA, there was no evidence that ELF-1 and SP1 bind together to the −52 ETS
oligonucleotide probe (SP1 represented the largest/slowest migrating complex). However,
cotransfection with ELF-1 and SP1 had an additive effect on VEGFR1 promoter activity, suggesting that
the 2 transcription factors interact functionally to promote expression. ELF-1 was originally described as
a regulator of T-cell–specific genes.  Subsequent studies revealed a role for ELF-1 in endothelial cell–
specific gene regulation. For example, ELF-1 has been shown to bind to and/or transactivate the
promoters for Tie-1, Tie-2, and endothelial nitric oxide synthase.  The current study adds VEGFR1
to the list of ELF-1–responsive genes in endothelial cells.
Similar to −52 ETS, the negatively acting −39 ETS consensus site also bound SP1. However, we failed to
detect binding of any ETS protein to this element. Indeed, the −39 ETS site was not directly identified by
MultiTF as a consensus binding site. The finding that the −52 ETS mutant (with an intact −39 ETS site)
was unresponsive to ELF-1 and/or SP1 expression in cotransfection assays suggests that SP1 binds to,
but does not activate, the proximal ETS site. Thus, it is possible that the −39 ETS motif sequesters SP1,
thereby inhibiting functional interactions between SP1 and the upstream −52 ETS motif.
Our results support the importance of the CREB/ATF binding element in mediating VEGFR1
expression. The data confirm earlier studies demonstrating a positive role for this site in transient
transfection assays.  In the latter studies, forskolin and dibutyryl-cyclic adenosine monophosphate
failed to activate the VEGFR1 promoter, suggesting that the CRE motif functioned independently of
cyclic adenosine monophosphate signaling.  Wakiya et al showed that a specific DNA-protein complex
formed on the CRE motif.  Using nuclear extracts from primary human endothelial cells, we have
shown that this complex consists of CREB, but not ATF2. The finding that CREB binds to an Hprt-
targeted human VEGFR promoter containing an intact CRE site, but not an identical promoter with a
mutation of CRE, provides further evidence for the role of CREB in mediating VEGFR1 expression in
vivo.
It was previously demonstrated that an EGR binding site between −16 and −24 plays a role in mediating
VEGFR1 expression in response to injury. In an in vitro wounding assay, both VEGFR and EGR-1 were
expressed at the edge of the denuded area.  A mutation of EGR binding site inhibited injury-induced
activation of the promoter, but had no effect on basal activity.  EMSA revealed inducible binding of
EGR-1 to the consensus EGR binding element, and in cotransfection assays EGR-1 induced the
expression of the VEGFR1 promoter.
Previous studies of EGR proteins in vascular biology have focused primarily on EGR-1 (reviewed in
Khachigian et al ). However, recent evidence points to an important role for EGR-3 in transducing














10/18/12 12:30 PMVascular Biology: Differential roles for ETS, CREB, and EGR binding sites in mediating VEGF receptor 1 expression in vivo
Page 9 of 19http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2798866/?report=printable
VEGF in DNA microarrays of HUVECs,  and VEGF- and fibroblast growth factor 2 (FGF-2)–induced
endothelial cell proliferation was attenuated by EGR-3 knockdown.  We have demonstrated that EGR-
3 has a far greater effect on VEGFR1 promoter activity compared with EGR-1 in cotransfection assays
(17-fold vs 4-fold induction, respectively; T.M. and W.C.A., unpublished observations, March 2009).
Moreover, siRNA-mediated knockdown of EGR-3 in VEGF-treated endothelial cells significantly
inhibits VEGFR1 mRNA expression (T.M. and W.C.A., unpublished observations, March 2009). In the
current study, we have shown that the EGR binding motif is capable of binding both recombinant EGR-1
and EGR-3. Given that both EGR-1 and EGR-3 are inducibly expressed in endothelial cells, it seems
likely that both isoforms contribute to the expression of VEGFR1.
We previously reported that in Hprt-targeted mice the wild-type VEGFR1 promoter directed expression
in blood vessels of all organs examined except the liver.  Expression was observed primarily in
endothelium. However, reporter gene activity was also detectable in some vascular smooth muscle cells
as well as in cardiomyocytes. In the current study, we targeted the Hprt locus of mice with VEGFR1
promoter-reporter gene constructs containing mutations of the −39 ETS, −52 ETS, CRE, or EGR
binding sites. We also generated a new line of mice targeted with wild-type VEGFR1-lacZ so that all
analyses could be carried out in sex-, age-, and generation-matched mice.
Consistent with the transient transfection results, mutations of the −52 ETS, CRE, and EGR binding
sites reduced reporter gene activity in vivo. Moreover, a mutation of the −39 ETS motif increased LacZ
expression in the intact endothelium. These changes paralleled those observed in transient
transfections. However, the in vivo results provided insights that were otherwise unapparent in vitro.
For example, mutation of CREB/ATF binding site had an equal if not greater inhibitory effect on
expression compared with mutation of −52 ETS, whereas the opposite was true in vitro. Despite the
readily detectable activity of the VEGFR1 promoter and most of its variants in several types of cultured
endothelial cells, expression was conspicuously absent in the liver of Hprt-targeted mice. Interestingly,
mutations of the various cis-regulatory motifs resulted in time-dependent and/or vascular bed–specific
changes in reporter gene activity. For example, the −52 ETS or CRE mutations were expressed in
embryonic but not normal adult endothelium. The EGR binding site mutation resulted in a clear
reduction in the endothelium of the diaphragm, but not the lung. Finally, the −52 ETS or CRE mutations
are reactivated during tumor angiogenesis, suggesting that other regulatory elements are capable of
promoting VEGFR1 expression in this pathologic setting. Indeed, phylogenetic footprinting of the
VEGFR1 promoter reveals additional consensus sites that are highly conserved across species (please see
supplemental Figures 1-2) and that may ultimately prove to play an important role in mediating spatial
and temporal expression of VEGFR1. Together, our findings suggest that endothelial cells from different
vascular beds use distinct regulatory mechanisms to control expression of VEGFR1.
To our knowledge, the current study is the first to systematically explore the functional relevance of
promoter elements in the context of single-copy–single-locus gene targeting. By controlling for copy
number and integration site, we can be confident that any differences in the pattern and/or levels of
expression are reflective of differences in the promoter. It is formally possible that such differences are
an artifact of fortuitous interactions between the targeted promoter and Hprt locus control elements.
Indeed, the gold standard approach would be to mutate the cis-regulatory elements in the endogenous
VEGFR1 locus. This limitation notwithstanding, the current study offers powerful proof of principle for
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Figure 1
Sequence conservation of the immediate upstream VEGFR1 promoter. Top part shows
evolutionary conservation of the promoter region between −7 and −125 (chr13:27967,272-27967,390)
using the UCSC Gene Browser. Blue/green tracks on the top part of the figure illustrate conservation of
the sequence in primates (top tracks), placental mammals (middle tracks), and vertebrae (bottom, light
blue/light green tracks) using the PhyloP and PhastCons packages (Cornell University), respectively.
Conserved elements identified by PhastCons are shown as magenta (primates), purple (placental
mammals), and brown (vertebrae) bars. Sequence alignments show conservation of the CRE motif at
−81, the −52 and −39 ETS motifs, and the EGR binding site at −25. Although highly conserved, the −39
ETS site was not identified as a binding site by MultiTF.
Figure 2
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ETS, CRE, and EGR binding sites contribute to basal expression of the VEGFR1 promoter
in primary human endothelial cells. (A) Wild-type (WT) and mutant cis-regulatory sequences used
in transfections and Hprt-targeted mice. The wild-type DNA sequence is shown on top (50-bp per line)
with each of the ETS, CRE, and EGR binding sites individually colored, and the 5′ untranslated region
underlined. The mutated sequences are shown underneath, underlined in parentheses. (B) WT or
mutant VEGFR1 promoters were coupled to luciferase in PGL3 and the resulting plasmids were
transiently transfected into HUVECs, HCAECs, or HPAECs. The results show the means and SDs of
luciferase light units (relative to untreated cells) obtained in triplicate from at least 3 independent
experiments. + indicates 0.1; **P < .01; ***P < .001.
Figure 3
10/18/12 12:30 PMVascular Biology: Differential roles for ETS, CREB, and EGR binding sites in mediating VEGF receptor 1 expression in vivo
Page 14 of 19http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2798866/?report=printable
ELF-1 and SP1 bind to the −52 ETS motif in the human VEGFR1 promoter and induce
promoter activity. (A) EMSA was performed with P-labeled −52 ETS probe in the absence (lane 1)
or presence of nuclear extract from HUVECs (lanes 2-7) In competition assays, a 10-fold or 50-fold
molar excess of unlabeled wild-type (lanes 3-4) or mutant (lanes 5-6) −52 ETS probe was added to the
reaction mixture. 
indicates specific DNA-protein complexes. (Based on EMSA in panel B, complexes a and c represent SP1
and ELF-1, respectively; the identity of complexes b and d is unknown). NS indicates nonspecific
complex. (B) EMSA was performed with P-labeled −52 ETS probe in the absence (lanes 1, 8, 11) or
presence of nuclear extract from HUVECs (lanes 2-7), recombinant SPI (lanes 9-10), or recombinant
ELF-1 (lanes 12-13). In supershift assays, nuclear extracts or recombinant protein was incubated in the
32
32
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presence of antibodies (indicated by prefix “a”) to ELF-1 (lane 3, 13), SP1 (lane 4, 10), ETS-1 (lane 5),
ETS-2 (lane 6), or control antibody (lane 7). 
 indicates SP1 and
ELF-1 DNA-protein complexes. (C) EMSA was performed with P-labeled consensus ETS-1 binding
probe (lanes 1-3) or −52 ETS (lanes 4-5) in the absence (lanes 1, 4) or presence of in vitro translated
ETS-1 ± antibodies to ETS-1 (lane 3). (D) HUVECs were transfected with control siRNA or siRNA
against ELF-1 and/or ETS-1. Real-time PCR was used to assay for mRNA expression of ELF-1, ETS-1, or
VEGFR1. The results show the means and SDs of mRNA expression (relative to control siRNA-
transfected cells) obtained in triplicate from 3 independent experiments. RQ indicates relative
quantitation. *P < .05; **P < .01; ***P < .001, relative to control siRNA. (E) ChIP assay was performed
using HUVECs. DNA was sheared and resulting DNA-protein complexes were immunoprecipitated in
the absence or presence of antibodies to ELF-1, SP1, or control IgG. Real-time PCR analysis was
performed using the precipitated DNA fragments and primers for VEGFR1 proximal region, which
included the −52 ETS site. (F) Cotransfection assay was carried out in HEK293 cells using 0.3 µg of
pcDNA3-SP1 expression vector or empty vector (PCI-pcDNA), and either wild-type VEGFR1-luc (WT) or
a similar construct containing a mutation of the −52 ETS site. Data represent mean ± SE of 6 replicates.
Luciferase light units are expressed as fold induction over the empty expression vector. (G)
Cotransfection assay was carried out in HUVECs using 0.3 µg of pcDNA3-SP1 expression vector or
empty vector (PCI-pcDNA), and either wild-type VEGFR1-luc (WT) or a similar construct containing a
mutation of the −52 ETS site. Data represent mean ± SE of 6 replicates. Luciferase light units are
expressed as fold induction over the empty expression vector. (F-G) *P < .05; **P < .01; ***P < .001,
relative to pCI + pcDNA.
Figure 4
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DNA-protein binding at the −39 ETS, CRE, and EGR binding motifs in the human VEGFR1
promoter. (A) EMSA was performed with P-labeled −39 ETS probe in the absence (lanes 1, 9, 12) or
presence of nuclear extract from HUVECs (lanes 2-8), recombinant SPI (lanes 10-11), or recombinant
ELF-1 (lanes 13-14). In competition assays, a 50-fold molar excess of unlabeled wild-type (lane 3) or
mutant (lane 4) −39 ETS probe was added to the reaction mixture. In supershift assays, nuclear extracts
or recombinant protein was incubated in the presence of antibodies (indicated by prefix “a”) to ELF-1
(lanes 5, 14), SP1 (lanes 6, 11), ETS-1 (lane 7), or control antibody (lane 8). The arrow indicates specific
SP1-DNA complex. NS indicates nonspecific complex. (B) EMSA was performed with P-labeled
consensus CRE probe in the absence (lane 1) or presence of nuclear extract from HUVECs (lanes 2-7). In
competition assays, a 50-fold molar excess of unlabeled wild-type (lane 3) or mutant (lane 4) CRE probe
was added to the reaction mixture. In supershift assays, nuclear extracts were incubated in the presence
of antibodies to CREB (lane 5), ATF2 (lane 6), or control antibody (lane 7). 
32
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 indicates specific CREB-
DNA complex; *, supershifted complex. (C) EMSA was performed with P-labeled EGR binding site
probe in the absence (lane 1) or presence of nuclear extract from HUVECs (lanes 2-5). In supershift
assays, nuclear extracts were incubated in the presence of antibodies to EGR-1 (lane 3), EGR-3 (lane 4),
or control antibody (lane 5). 
 indicates DNA-protein
complex. (D) EMSA was performed with P-labeled EGR binding site probe in the absence (lanes 1-2)
or presence of recombinant EGR-1 (lanes 3-8). In competition assays, a 50-fold molar excess of
unlabeled wild-type (lane 4) or mutant (lanes 5-6) EGR probe was added to the reaction mixture. In
supershift assays, recombinant protein was incubated in the presence of antibodies to EGR-1 (lane 7) or
control antibody (lane 8). * indicates supershifted complex. (E) EMSA was performed with P-labeled
EGR binding site probe in the absence (lanes 1-2) or presence of recombinant EGR-3 (lanes 3-8). In
competition assays, a 50-fold molar excess of unlabeled wild-type (lane 4) or mutant (lanes 5-6) EGR
probe was added to the reaction mixture. In supershift assays, recombinant protein was incubated in the





10/18/12 12:30 PMVascular Biology: Differential roles for ETS, CREB, and EGR binding sites in mediating VEGF receptor 1 expression in vivo
Page 18 of 19http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2798866/?report=printable
LacZ staining of diaphragm from Hprt-targeted mice carrying wild-type or mutant
VEGFR1 promoters. Diaphragms were harvested from 6- to 8-week-old F2 male Hprt-targeted mice
carrying wild-type (WT) or mutant VEGFR1-lacZ transgenes and processed in parallel for whole-mount
staining with X-Gal. In each panel, the diaphragm from WT VEGFR1 transgenic is on the right, and the
diaphragm from the mutant mouse is on the left. The exposure time in bottom right panel was reduced
compared with other panels. Whole-mount diaphragms were analyzed under a Nikon SMZ-U dissecting
microscope, and microphotographs were collected using a Nikon Coolpix 8400 camera.
Figure 6
LacZ staining of tissue sections. Cryosections were collected from heart, lung, kidney, and skeletal
muscle (Sk mu) harvested from 6- to 8-week-old F2 male Hprt-targeted mice carrying wild-type, −39
ETSm, or EGRm VEGFR1 transgenes and stained with X-Gal. Serial sections were processed for CD31
immunohistochemistry. Images were obtained using a 20× objective. Bar, 100µM. Lac-Z-stained
sections were counterstained with eosin. Slides were analyzed under a Zeiss Axio Imager upright
microscope, and photomicrographs were collected using a Zeiss Axiocam MRc camera and Axiovision
4.6.3 image acquisition software.
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Figure 7
β-Galactosidase activity and CREB/ELF-1 binding assays. (A) β-Galactosidase activity of protein
extracts from various organs of the Hprt-targeted mice. Data represent mean ± SE of 4 replicates. *P <
.05; **P < .01; **P < .001. n.s., not significant. (B-C) ChIP assay was performed using mouse heart
endothelial cells from Hprt-targeted mice carrying a mutation of the CRE site (CREm) or −52 ETS site
(−52ETSm). The sheared DNA samples were analyzed by 1.7% agarose gel. Resulting DNA-protein
complexes were immunoprecipitated in the absence or presence antibodies to ELF-1 or CREB. Real-time
PCR analysis was performed using the precipitated DNA fragments and primers for the human proximal
promoter and LacZ cDNA (C).
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